Download PDF
Exp Clin Endocrinol Diabetes 2016; 124(06): 380-384
DOI: 10.1055/s-0042-104497
Article
© Georg Thieme Verlag KG Stuttgart · New York

Cumulative Risk of Metabolic Syndrome Correlated with the Coexistence of (-1306C/T) and Altered Circulating MMP2 level

S. S. Yadav
1   Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow
,
R. K. Mandal
2   Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India
,
M. K. Singh
5   Department of Biochemistry, MLN Medical College, Allahabad
,
P. Dwivedi
1   Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow
,
R. Sethi
3   Department of Cardiology King George’s Medical University, Lucknow, India
,
K. Usman
4   Department of Medicine King George’s Medical University, Lucknow, India
,
S. Khattri
1   Department of Pharmacology and Therapeutics, King George’s Medical University, Lucknow
› Author Affiliations
Further Information

Publication History

received 29 October 2015
first decision 18 February 2016

accepted 29 February 2016

Publication Date:
24 May 2016 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Interindividual genetic variations and environmental factors both play pivotal roles in the pathogenesis of metabolic syndrome (MetS). The rationale of this study conducted was to analyze the association of Matrix Metalloproteinase (MMP) gene variants, MMP-1 (-1607 1G/2G) and MMP-2 (-1306 C/T) with susceptibility to MetS and its effect on serum MMP level.

Methods: Study involved 370 subjects with 1:1 distribution of cases and controls. Patients were recruited according to modified NCEP-ATP III criteria for MetS. Clinical, biochemical analysis, PCR-RFLP and ELISA methods were employed for genotyping and estimation of serum MMP level.

Results: Significantly (p<0.001) higher Serum MMP-2 (39.13±19.96 ng/ml) was detected in cases as compared to controls. The MMP-2 (-1306 C/T) was significantly associated with the risk of MetS. The variant genotype TT was significantly associated with increased risk of MetS. (p=0.032; OR=2.31; 95%CI=1.07–4.97). No significant association of MMP-1(-1607 1G/2G) was found with risk of MetS.

Conclusion: Our study concluded that presence of MMP-2 (-1306 C/T) might be associated the risk of MetS. Serum MMP2 level was significantly higher in patients and correlated with clinical parameters of MetS. Clinical implication of the work may help to identify the individuals with high risk of MetS and further complications.

Key words

insulin resistance - matrix metalloproteinase - metabolic syndrome - polymorphism
 

  • References

  • 1 Belo VA, Luizon MR, Carneiro PC et al. Effect of metabolic syndrome risk factors and MMP-2 genetic variations on circulating MMP-2 levels in childhood obesity. Mol Biol Rep 2013; 40: 2697-2704
    CrossrefPubMedGoogle Scholar
  • 2 Beranek 1 M, Kolar P, Tschoplova S et al. Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathy. Mol Vis 2008; 14: 1114-1121
    PubMedGoogle Scholar
  • 3 Berg G, Miksztowicz V, Schreier L. Metalloproteinases in metabolic syndrome. Clin Chim Acta 2011; 412: 1731-1739
    CrossrefPubMedGoogle Scholar
  • 4 Cameron AJ, Shaw JE, Zimmet PZ. The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004; 2: 351-375
    PubMedGoogle Scholar
  • 5 Cornier MA, Dabelea D, Hernandez TL et al. The metabolic syndrome. Endocr Rev 2008; 29: 777-822
    CrossrefPubMedGoogle Scholar
  • 6 Delgado-Enciso I, Gonzalez-Hernandez NA, Baltazar-Rodriguez LM. Association of matrix metalloproteinase-2 gene promoter polymorphism with myocardial infarction susceptibility in a Mexican population. J Genet 2009; 2: 249-252
    PubMedGoogle Scholar
  • 7 Drzewoski J, Sliwińska A, Przybyłowska K et al. Gene polymorphisms and antigen levels of matrix metalloproteinase1 in type 2 diabetes mellitus coexisting with coronary heart disease. Kardiol Pol 2008; 66: 1042-1048
    PubMedGoogle Scholar
  • 8 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428
    CrossrefPubMedGoogle Scholar
  • 9 Francke S, Manraj M, Lacquemant C et al. A genome-wide scan for coronary heart disease suggests in Indo-Mauritians a susceptibility locus on chromosome 16p13 and replicates linkage with the metabolic syndrome on 3q27. Hum Mol Genet 2001; 10: 2751-2765
    CrossrefPubMedGoogle Scholar
  • 10 Grundy SM. Metabolic Syndrome pandemic. Arterioscler Thromb Vasc Biol 2008; 28: 629-636
    CrossrefPubMedGoogle Scholar
  • 11 Huang HL, Wu S, Hsu LA et al. Genetic variants associated with circulating MMP1 levels near matrix metalloproteinase genes on chromosome 11q21-22 in Taiwanese: interaction with obesity. BMC Med Genet 2013; 4: 14-30
    PubMedGoogle Scholar
  • 12 IDF International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. http://www.idf.org/metabolic-syndrome 2006
    PubMedGoogle Scholar
  • 13 Kaur J. A Comprehensive Review on Metabolic Syndrome. Cardiology Research and Practice 2014; 11: 943162
    PubMedGoogle Scholar
  • 14 Lijnen HR, Maquoi E, Demeulemeester D et al. Modulation of fibrinolytic and gelatinolytic activity during adipose tissue development in a mouse model of nutritionally induced obesity. Thromb Haemost 2002; 88: 345-353
    PubMedGoogle Scholar
  • 15 Miller SA, Dykes DD, Polesky HF. Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1998; 3: 1215
    PubMedGoogle Scholar
  • 16 Misra A, Wasir JS, Pandey RM. An evaluation of candidate definitions of the metabolic syndrome in adult Asian Indians. Diabetes Care 2005; 28: 398-403
    CrossrefPubMedGoogle Scholar
  • 17 Nagase H, Woessner Jr JF. Matrix metalloproteinases. J BiolChem 1999; 274: 21491-21494
    PubMedGoogle Scholar
  • 18 Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573
    CrossrefPubMedGoogle Scholar
  • 19 Pollex RL, Hegele RA. Genetic determinants of the metabolic syndrome. Nat Clin Pract Cardiovasc Med 2006; 3: 482-489
    CrossrefPubMedGoogle Scholar
  • 20 Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999; 274: 29130-29137
    CrossrefPubMedGoogle Scholar
  • 21 Roman-Garcia P, Coto E, Reguero JR et al. Matrix metalloproteinase 1 promoter polymorphisms and risk of myocardial infarction: a case control study in a Spanish population. Coron Artery Dis 2009; 20: 383-386
    CrossrefPubMedGoogle Scholar
  • 22 Rutter JL, Mitchell TI, Butticè G et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res 1998; 58: 5321-5355
    PubMedGoogle Scholar
  • 23 Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol 1998; 10: 602-608
    CrossrefPubMedGoogle Scholar
  • 24 Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behavior. Annul Rev Cell Dev Biol 2001; 17: 463-516
    PubMedGoogle Scholar
  • 25 Van-Hul M, Lijnen HR. A functional role of gelatinase A in the development of nutritionally induced obesity in mice. J Thromb Haemost 2008; 6: 1198-1206
    CrossrefPubMedGoogle Scholar
  • 26 Yadav SS, Mandal RK, Singh MK et al. Genetic variants of matrix metalloproteinase (MMP2) gene influence metabolic syndrome susceptibility. Genet Test Mol Biomarkers 2014; 18: 88-92
    CrossrefPubMedGoogle Scholar
  • 27 Ye S. Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biology 2000; 19: 623-629
    CrossrefPubMedGoogle Scholar
  • 28 Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J 2003; 24: 1668-1671
    CrossrefPubMedGoogle Scholar